Research has been seen as less objectionable than other forms of interactions with drug companies, but 10 percent of researchers have multiple ties among the nine companies analyzed. That raises questions about doctors’ impartiality.
Research has been seen as less objectionable than other forms of interactions with drug companies, but 10 percent of researchers have multiple ties among the nine companies analyzed. That raises questions about doctors’ impartiality.